Roche provides update on Phase III Skyscraper-01 study in PD-L1-high metastatic non-small cell lung cancer
SKYSCRAPER-01 is ongoing and the study remains blinded to patients and investigators
SKYSCRAPER-01 is ongoing and the study remains blinded to patients and investigators
If approved, Tecentriq will be the first and only cancer immunotherapy available for certain people with early-stage NSCLC in Europe
Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting
Roche is notifying healthcare professionals and patients in the US about this withdrawal. Patients being treated with Tecentriq for PD-L1-positive mTNBC should discuss their care with their healthcare provider
Subscribe To Our Newsletter & Stay Updated